ROTHBLATT MARTINE A sold $4.9M of UTHR (indirect holdings)
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $518.96 ($514.82–$522.88, $4.93M total) across 9 trades on 2026-07-31 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size ($4.93M) and that it was executed under a pre-arranged 10b5-1 plan, which reduces interpretive weight versus discretionary selling.
Market read
Traders may monitor for follow-on insider activity, but this filing alone does not provide new operational or financial information.
What to watch
The filing specifies indirect holdings and multiple small trades; without context on total holdings or prior sale cadence, directional inference is weak.
Background
The article is an SEC Form 4 insider transaction disclosure for United Therapeutics, reported via EDGAR.
Ticker impact
United Therapeutics Form 4 shows CEO Chairperson Martine Rothblatt sold $4.93M of UTHR via an open-market sale under a 10b5-1 plan.
Likely limited, short-lived sentiment impact; no clear directional fundamental signal from the filing alone.
The filing is a routine 10b5-1 open-market sale with no accompanying guidance, deal, or regulatory/clinical catalyst in the text.
Market effects
Minimal; insider-sale disclosures rarely reset sector expectations without additional company-specific catalysts.
None indicated.
None indicated.
Counterpoint
10b5-1 sales often reflect scheduled liquidity needs rather than bearish views, so the market may discount the signal.
Key entities
- issuerUnited Therapeutics Corp
Subject of the Form 4 insider transaction disclosure.
- insiderMartine A. Rothblatt
Chairperson and CEO who reported an open-market sale of UTHR shares via a 10b5-1 plan.
